Merck Stock Rises as Japan Approves Keytruda Injection

Merck & Co.'s stock price gained on September 23, 2026, after Japan cleared its Keytruda injection for all existing local indications. The approval adds a faster under-skin dosing option to Merck's leading oncology franchise.

The company's market capitalization stood at $372.32 billion as of September 23, with the stock trading at $151.00 on the NYSE. This is close to its 52-week high of $156.92, which it reached in 2026.

In related news, Merck reported a 5.1% increase in second-quarter revenue from the same quarter in the prior year, reaching $16.61 billion according to MarketBeat on September 22, 2026. However, its reported quarterly earnings per share (EPS) of negative $0.13 fell below the consensus estimate of negative $0.26.